Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 141-150 of 639 results
Theranostics, 2023 • April 23, 2023
The study used a drug screening assay in larval zebrafish to identify Cimetidine, a histamine H2 receptor antagonist, as an immunomodulator after spinal cord injury. Cimetidine modulated the immune re...
KEY FINDING: Cimetidine, an over-the-counter H2 receptor antagonist, reduced il-1β expression in zebrafish and partially rescued impaired regeneration in the irf8 zebrafish mutant model for chronic inflammation.
Rev Bras Ortop, 2023 • August 2, 2022
The study evaluated the current practice of using methylprednisolone sodium succinate (MPSS) in acute spinal cord injuries (ASCIs) among spine surgeons from Iberolatinoamerican countries. A survey was...
KEY FINDING: Only 37.9% of surgeons reported using corticosteroids in the initial management of ASCIs.
J Med Chem, 2023 • June 22, 2023
This study introduces novel biphenyl Au(III) complexes with bisphosphine ligands, demonstrating their stability and mild mitochondrial uncoupling activity. The complex Au-3 exhibits potent anticancer ...
KEY FINDING: The gold(III) complex Au-3 exhibits significant tumor growth inhibition in a metastatic TNBC mouse model.
Clinical Infectious Diseases, 2023 • June 3, 2023
This study evaluated the outcomes of customized phage therapy for 12 patients with difficult-to-treat antimicrobial-resistant infections. The customized phages were generated for 12 patients. After tr...
KEY FINDING: 42% (5/12) of cases showed bacterial eradication after treatment.
bioRxiv, 2023 • November 17, 2023
This study investigates the potential of ampakines to improve bladder function following spinal cord injury (SCI) in rats. The research focuses on the acute effects of intravenous ampakine administrat...
KEY FINDING: Ampakine CX1739 significantly reduced the pressure threshold for inducing bladder contraction in rats with SCI.
Journal of Nanobiotechnology, 2023 • January 1, 2023
The study introduces M@8G, a nano-delivery platform designed to target and treat secondary spinal cord injury (SCI). M@8G consists of 8-gingerol (8G) loaded into mesoporous polydopamine (M-PDA). Resul...
KEY FINDING: M@8G can penetrate the blood-spinal cord barrier to enrich the spinal cord injury site.
The Journal of Spinal Cord Medicine, 2023 • July 1, 2023
This study assessed high-risk opioid prescription metrics among individuals with chronic SCI, including chronic use, high-dose therapy, and concurrent BSH use. The findings indicate a concerning numbe...
KEY FINDING: Over half (53%) of the individuals filled an opioid prescription in years 2–3 after injury.
JCI Insight, 2023 • July 24, 2023
This study identifies OATP1B-type transporters as mediators of vincristine uptake in DRG neurons and demonstrates that inhibiting these transporters can prevent VIPN. Genetic deficiency or pharmacolog...
KEY FINDING: OATP1B3 (human) and OATP1B2 (mouse) are identified as neuronal transporters that regulate the uptake of vincristine into DRG neurons.
Biomedicines, 2023 • May 26, 2023
The study evaluated the anti-neuropathic activity of COR167, a novel selective CB2 agonist, in a preclinical model of peripheral neuropathy (SNI). Oral administration of COR167 reduced neuropathic pai...
KEY FINDING: Oral COR167 attenuated mechanical allodynia and thermal hyperalgesia in a dose-dependent manner after acute and repeated administration, without tolerance induction.
Adv Ther, 2023 • July 7, 2023
This study aimed to understand treatment/injection patterns of botulinum toxins type A (BoNT-As) and the characteristics, healthcare resource utilization (HCRU), and costs among patients with spastici...
KEY FINDING: These findings demonstrate significantly higher healthcare costs among patients with spasticity or cervical dystonia, and further confirm the economic burden associated with disease management.